Sitagliptin / Metformin hydrochloride Mylan Union européenne - français - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Metformine Viatris 850 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

metformine viatris 850 mg compr. pellic.

viatris gx bv-srl - chlorhydrate de metformine 850 mg - eq. metformine 662,9 mg - comprimé pelliculé - 850 mg - chlorhydrate de metformine 850 mg - metformin

Metformine Sandoz 850 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

metformine sandoz 850 mg compr. pellic.

sandoz sa-nv - chlorhydrate de metformine 850 mg - eq. metformine 662,9 mg - comprimé pelliculé - 850 mg - chlorhydrate de metformine 850 mg - metformin

Sitagliptin / Metformin hydrochloride Sun Union européenne - français - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Vildagliptin / Metformin hydrochloride Accord Union européenne - français - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).

Sitagliptin / Metformin hydrochloride Accord Union européenne - français - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sitagliptin/Metformin Sandoz 50 mg - 850 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sitagliptin/metformin sandoz 50 mg - 850 mg compr. pellic.

sandoz sa-nv - chlorhydrate de sitagliptine monohydraté 56,685 mg - eq. sitagliptine 50 mg; chlorhydrate de metformine 850 mg - comprimé pelliculé - 50 mg - 850 mg - chlorhydrate de sitagliptine monohydraté 56.685 mg; chlorhydrate de metformine 850 mg - metformin and sitagliptin

Sitagliptin/Metformin Sandoz GmbH 50 mg - 850 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sitagliptin/metformin sandoz gmbh 50 mg - 850 mg compr. pellic.

sandoz gmbh - chlorhydrate de sitagliptine monohydraté 56,7 mg - eq. sitagliptine 50 mg; chlorhydrate de metformine 850 mg - comprimé pelliculé - 50 mg - 850 mg - chlorhydrate de sitagliptine monohydraté 56.7 mg; chlorhydrate de metformine 850 mg - metformin and sitagliptin

APO-SITAGLIPTIN-METFORMIN Comprimé Canada - français - Health Canada

apo-sitagliptin-metformin comprimé

apotex inc - chlorhydrate de metformine; sitagliptine (phosphate de sitagliptine monohydraté) - comprimé - 850mg; 50mg - chlorhydrate de metformine 850mg; sitagliptine (phosphate de sitagliptine monohydraté) 50mg

Metformine Viatris 1000 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

metformine viatris 1000 mg compr. pellic.

viatris gx bv-srl - chlorhydrate de metformine 1000 mg - eq. metformine 780 mg - comprimé pelliculé - 1000 mg - chlorhydrate de metformine 1000 mg - metformin